- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
ideaPoint Launches New Partnering-Opportunity Software
Anaqua’s ideaPoint has announced the launch of new software that "will simplify the identification and capture of key partnering opportunities and novel innovative ideas".
The software, ideaPoint 5.0, enables organizations to accelerate the speed and efficiency of evaluating, tracking, and managing innovation and identifying and capitalizing on opportunities for partnerships and collaborations, whether internal or external.
One of the reported key enhancements is Mobile Scout, which enables users to capitalize on potential partnering opportunities more easily and effectively through a mobile device or tablet. Users can quickly capture meetings with potential partners and tag their entries with key information. They can turn meeting notes into opportunities with one click or set reminders to keep track of potential opportunities. In addition, they can easily report on the ROI of events based on leads generated to determine the best way to allocate future resources.
ideaPoint will be presenting the new software at BioEurope on November 5 –7 and participating in the Innovation Roundtable Nov 6– 8, both in Copenhagen, Denmark.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
